R

    Recursion Pharmaceuticals Inc (RXRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.40
    +0.06 (+1.80%)

    Market Cap: $1.79B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(10/22)
    Avg Surprise
    -22.84%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.23
    Range$-0.25 - $-0.20
    6 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.23-0.5%
    60d ago$-0.23-0.5%
    30d ago$-0.23-0.5%
    7d ago$-0.23-0.8%
    Current$-0.23
    Revenue Consensus
    $14M
    Range$7M - $30M
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.25 - $-0.17
    7 analysts
    Revenue Consensus
    $719340
    Range$-15563370 - $30M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-0.23---
    Jun 26
    		$-0.25$-0.23-8.70%Miss+39.0%
    Mar 26
    		$-0.22$-0.26+15.38%Beat+56.0%
    Dec 25
    		$-0.21$-0.30+30.00%Beat+60.4%
    Sep 25
    		$-0.36$-0.38+5.26%Beat-5.9%
    Jun 25
    		$-0.41$-0.35-17.14%Miss-2.5%
    Mar 25
    		$-0.50$-0.52+3.85%Beat-28.2%
    Dec 24
    		$-0.53$-0.42-27.16%Miss-26.2%
    Sep 24
    		$-0.34$-0.33-3.03%Miss+20.9%
    Jun 24
    		$-0.40$-0.38-5.26%Miss-5.3%
    Mar 24
    		$-0.39$-0.43+9.30%Beat-14.7%
    Dec 23
    		$-0.42$-0.45+6.67%Beat-40.0%
    Sep 23
    		$-0.43$-0.39-10.26%Miss-22.9%
    Jun 23
    		$-0.38$-0.37-2.70%Miss+0.0%
    Mar 23
    		$-0.34$-0.35+2.86%Beat-3.0%
    Dec 22
    		$-0.30$-0.24-25.00%Miss+21.1%
    Sep 22
    		$-0.35$-0.38+7.89%Beat-25.0%
    Jun 22
    		$-0.38$-0.37-2.70%Miss-22.6%
    Mar 22
    		$-0.33$0.10-430.00%Miss-43.5%
    Dec 21
    		$-0.38$-0.31-22.58%Miss-52.0%
    Sep 21
    		$-0.28$-0.28+0.00%Beat-
    Jun 21
    		$-0.31$-0.24-29.17%Miss-
    Mar 21
    		$-0.23$-0.23+0.00%Beat-
    Dec 20
    		$-0.25$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.27EV/EBITDA-5.31x
    Price/FCF-5.14xFCF Yield-19.46%
    Profitability
    Profit Margin0.00%Operating Margin-1760.00%
    ROE-56.60%ROIC-55.84%
    Financial Health
    Debt/Equity0.02xInterest CoverageN/A
    Current Ratio5.03xQuick Ratio5.03x
    Trading Statistics
    Beta1.05Avg Volume15.33M
    52-Week High$7.1852-Week Low$2.77

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.39
    SMA 20$3.31
    SMA 50$3.31
    SMA 200$3.66
    EMA 10$3.38
    EMA 20$3.33
    EMA 50$3.30
    EMA 200$3.76

    MACD

    Line: 0.05Signal: 0.04Hist: 0.02

    ADX

    ADX: 12.4+DI: 25.4-DI: 23.6

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down4.0
    PSAR$3.09

    Bollinger Bands

    Upper Band$3.59
    Lower Band$3.04
    %B Position1649%(Upper)
    Band Width0.66

    RSI (14-Day)

    Neutral
    52.9

    Momentum Oscillators

    Stoch %K66.7
    Stoch %D72.9
    Williams %R-32.4
    ROC (10d)9.3%
    Momentum0.29
    CCI (20d)30.0
    MFI (14d)41.8

    Volatility Measures

    ATR (14d)$0.19(5.7%)
    StdDev (20d)0.14
    Hist Vol77.0%(High)

    Volume Flow

    VWAP$3.35
    OBV-672.4M
    AD Line-1.1B
    CMF (20d)0.152

    Volume Metrics

    Avg Vol (20d)15.4M
    Vol Ratio0.9x
    VWMA (20d)$3.34

    Pivot Points

    R3$3.56
    R2$3.51
    R1$3.42
    Pivot Point$3.37
    S1$3.28
    S2$3.23
    S3$3.14

    Advanced Oscillators

    TSI6.73
    Ultimate Osc53.7
    KST43.62

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.67M$6.47M$35.54M$5.17M$19.22M$14.74M$4.55M$26.08M$14.42M$13.79M$10.89M$10.53M
    Cost of Revenue$11.49M$12.49M$14.28M$14.69M$20.16M$21.83M$12.79M$12.08M$9.20M$11.17M$9.88M$10.88M
    Gross Profit$-3,821,000$-6,018,000$21.26M$-9,512,000$-938,000$-7,084,000$-8,248,000$14.00M$5.22M$2.63M$1.01M$-344,000
    Operating Expenses$131.15M$122.49M$129.60M$162.69M$175.29M$184.28M$175.52M$112.36M$105.76M$98.97M$99.94M$99.21M
    R&D$89.61M$87.90M$95.94M$121.06M$128.64M$129.63M$98.33M$74.60M$73.93M$67.56M$69.48M$70.01M
    SG&A$41.53M$34.59M$33.66M$41.63M$46.65M$54.65M$77.19M$37.76M$31.83M$31.41M$30.46M$29.20M
    Operating Income$-134,968,000$-128,505,000$-108,335,000$-172,202,000$-176,227,000$-191,368,000$-183,767,000$-98,354,000$-100,543,000$-96,340,000$-98,930,000$-99,550,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$11.28M$0$0$0$0$0$0
    Income Before Tax$-131,006,000$-122,108,000$-108,103,000$-162,250,000$-171,897,000$-202,645,000$-178,898,000$-95,675,000$-98,063,000$-92,152,000$-97,058,000$-93,017,000
    Income Tax Expense$-1,000$-4,604,000$19,000$3,000$0$-158,000$8,000$167,000$-523,000$-779,000$-4,062,000$0
    Net Income$-131,005,000$-117,504,000$-108,122,000$-162,253,000$-171,897,000$-202,487,000$-178,906,000$-95,842,000$-97,540,000$-91,373,000$-92,996,000$-93,017,000
    EBITDA$-112,839,000$-102,435,000$-88,625,000$-141,207,000$-148,048,000$-183,314,000$-165,947,000$-88,477,000$-89,095,000$-84,775,000$-89,505,000$-85,439,000
    EBIT$-131,006,000$-122,108,000$-108,103,000$-162,250,000$-171,897,000$-202,645,000$-178,898,000$-95,675,000$-98,063,000$-92,152,000$-97,058,000$-93,017,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RXRX

    News

    RXRX | Recursion Pharmaceuticals, Inc. Class Financials - Revenue Breakdown

    This page provides a detailed financial overview of Recursion Pharmaceuticals, Inc. (RXRX), focusing on its revenue breakdown, alongside other financial data points like insider trading, institutional holdings, analyst ratings, and executive compensation. It notes the absence of specific revenue breakdown by segment or geography data and also lacks recent Congressional trading, corporate lobbying, and new patent grants. The article highlights the company's profile as a clinical-stage biotechnology firm and offers tools for advanced analysis.

    Quiver Quantitative•8/23/26•
    Neutral

    Recursion Pharmaceuticals (RXRX) Is Down 5.5% After Q2 Revenue Drop And Narrower Losses - What's Changed

    Recursion Pharmaceuticals (RXRX) saw a 5.5% drop after its Q2 2026 earnings report revealed a revenue decrease to US$7.67 million from US$19.22 million year-over-year, despite narrowing its net loss. The company's investment narrative continues to hinge on its AI-enabled drug discovery platform and advancing early-stage oncology trials, with analysts noting its potential for significant upside if clinical assets convert into successful drug programs. However, concerns remain regarding cash burn, reliance on external funding, and the need for future capital as R&D progresses.

    Sahm•8/19/26•
    Somewhat-Bearish

    Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes

    Recursion Pharmaceuticals (NASDAQ: RXRX) Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on August 17, 2026, to satisfy tax obligations related to the net settlement of restricted stock units. This action was solely for tax purposes and not a market sale, reducing his direct holdings to 1,043,837 shares. The price per share for the tax withholding was $3.16.

    Stock Titan•8/18/26•
    Neutral

    Recursion (NASDAQ: RXRX) CFO has 25,018 shares withheld for taxes

    Recursion (NASDAQ: RXRX) CFO Ben R. Taylor had 25,018 shares of Class A Common Stock withheld on August 17, 2026, to cover tax withholding obligations related to the net settlement of restricted stock units. The shares were valued at $3.16 each for this transaction. Following this event, Taylor directly holds 1,076,858 shares of Class A Common Stock.

    Stock Titan•8/18/26•
    Neutral

    Recursion (NASDAQ: RXRX) CEO's 80K shares withheld for RSU taxes

    Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) CEO Najat Khan had 80,498 shares of Class A Common Stock withheld on August 17, 2026, to cover tax obligations related to the net settlement of restricted stock units (RSUs). These shares were not sold in an open-market transaction, and after the withholding, Khan directly holds 2,095,298 shares. The value used for tax withholding was $3.16 per share.

    Stock Titan•8/18/26•
    Neutral

    Frequently Asked Questions About RXRX

    Does RXRX pay dividends?
    Recursion Pharmaceuticals Inc (RXRX) does not currently pay a regular dividend.
    What is RXRX's market cap?
    Recursion Pharmaceuticals Inc (RXRX) has a market capitalization of $1.79B with a current stock price of $3.40.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In